Diurnal is a commercial-stage specialty pharmaceutical company focused on diseases of the endocrine system. Its drugs target conditions where medical need is currently unmet, with the aim of becoming a global endocrine leader. Alkindi®, soon to be accompanied by Efmody®, continues to be rolled out throughout Europe. The results presentation highlighted three important clinical trials that are due to start in 2H’21 and aimed at delivering on the company’s strategic goal. The current cash resource is expected to be sufficient to complete these trials and to get Diurnal’s core commercial European cortisol deficiency franchise through to profitability.
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
All set for three pivotal trials
- Published:
16 Sep 2021 -
Author:
Martin Hall -
Pages:
19
Diurnal is a commercial-stage specialty pharmaceutical company focused on diseases of the endocrine system. Its drugs target conditions where medical need is currently unmet, with the aim of becoming a global endocrine leader. Alkindi®, soon to be accompanied by Efmody®, continues to be rolled out throughout Europe. The results presentation highlighted three important clinical trials that are due to start in 2H’21 and aimed at delivering on the company’s strategic goal. The current cash resource is expected to be sufficient to complete these trials and to get Diurnal’s core commercial European cortisol deficiency franchise through to profitability.